To diagnose and treat a patient with rare lupus erythematosus-like syndrome and antineutrophil cytoplasmic antibodies (ANCA) positive vasculitis with graves’ disease by applying the approach of evidence-based medicine. Clinical problems were raised based on the patient condition and PubMed (1966-2003), CBM (1978-2003), EMBASE (1974-2003) were searched for the related information. We found that the best explaination for this case was antithyroid drugs’ side effect, and the patient was obvious better after treatment.
Citation：
YANG Lichu an,XI AO Jian,LI Zi,SHU Baihai,JI Ling,LIU Xianrong,FAN Junming. Evidence-Based Diagnosis and Treatment of Lupus Erythematosus-Like Syndrome Induced by Anti-Thyroid Drugs. Chinese Journal of Evidence-Based Medicine, 2004, 04(7): 499-502. doi:
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
［1］Mathieu E,Fain O,Sitbon M,Thomas M.Systemic adverse effect of antithyroid drugs[J].Clin Rheumatol,1999; 18(1):66-68.
|
| 2. |
［2］Rodrigue S,Laborde H,Catoggio PM.Systemic lupus erythematosus and thyrotoxicosis:a hitherto little recognised association.Ann[J].Rheum Dis,1989; 48(5):424-427.
|
| 3. |
［3］Xu X,Zhao M,Zhang Y,Guo X,Wang H.Clinicopathological characteristics of propylthiouracil-induced antineutrophil cytoplasmic antibodies-positive vasculitis and their target antigens:a report of 4 cases and literature review[J].Chinese Journal of Internal Medicine,2002; 41(6):404-407.
|
| 4. |
徐旭东,赵明辉,章友康,郭晓惠,王海燕.丙基硫氧嘧啶导致的抗中性粒细胞胞质抗体阳性小血管炎及其靶抗原研究[J].中华内科学杂志,2002; 41(6):404～407.
|
| 5. |
［4］Yamada A,Sato K,Hara M,Tochimoto A,Takagi S,Hizuka N,Takano K.Propylthiouracil-induced lupus-like syndrome developing in a Graves’ patient with a sibling with systemic lupus erythematosus[J].Intern Med,2002; 41(12):1 204-1 208.
|
| 6. |
［5］Kawasaki Y,Suzuki J,Sike T,Isome M,Nozawa R,Suzuki S,Kume K,Suzuki H.A pediatric case of myeloperoxidase-antineutrophil cytoplasmic (ANCA)-related crescentic glomerulonephritis associated with propylthiouracil treatment for Graves’ disease[J].Nippon Jinzo Gakkai Shi,1998; 40(8):612-617.
|
- 1. ［1］Mathieu E,Fain O,Sitbon M,Thomas M.Systemic adverse effect of antithyroid drugs[J].Clin Rheumatol,1999; 18(1):66-68.
- 2. ［2］Rodrigue S,Laborde H,Catoggio PM.Systemic lupus erythematosus and thyrotoxicosis:a hitherto little recognised association.Ann[J].Rheum Dis,1989; 48(5):424-427.
- 3. ［3］Xu X,Zhao M,Zhang Y,Guo X,Wang H.Clinicopathological characteristics of propylthiouracil-induced antineutrophil cytoplasmic antibodies-positive vasculitis and their target antigens:a report of 4 cases and literature review[J].Chinese Journal of Internal Medicine,2002; 41(6):404-407.
- 4. 徐旭东,赵明辉,章友康,郭晓惠,王海燕.丙基硫氧嘧啶导致的抗中性粒细胞胞质抗体阳性小血管炎及其靶抗原研究[J].中华内科学杂志,2002; 41(6):404～407.
- 5. ［4］Yamada A,Sato K,Hara M,Tochimoto A,Takagi S,Hizuka N,Takano K.Propylthiouracil-induced lupus-like syndrome developing in a Graves’ patient with a sibling with systemic lupus erythematosus[J].Intern Med,2002; 41(12):1 204-1 208.
- 6. ［5］Kawasaki Y,Suzuki J,Sike T,Isome M,Nozawa R,Suzuki S,Kume K,Suzuki H.A pediatric case of myeloperoxidase-antineutrophil cytoplasmic (ANCA)-related crescentic glomerulonephritis associated with propylthiouracil treatment for Graves’ disease[J].Nippon Jinzo Gakkai Shi,1998; 40(8):612-617.
